Biogen Price to Book Ratio 2010-2022 | BIIB
Historical price to book ratio values for Biogen (BIIB) over the last 10 years. The current price to book ratio for Biogen as of July 01, 2022 is 2.76.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Biogen Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2022-07-01 |
210.63 |
|
2.77 |
| 2022-03-31 |
210.60 |
$76.07 |
2.77 |
| 2021-12-31 |
239.92 |
$74.56 |
3.22 |
| 2021-09-30 |
282.99 |
$74.08 |
3.82 |
| 2021-06-30 |
346.27 |
$75.22 |
4.60 |
| 2021-03-31 |
279.75 |
$70.80 |
3.95 |
| 2020-12-31 |
244.86 |
$70.12 |
3.49 |
| 2020-09-30 |
283.68 |
$69.81 |
4.06 |
| 2020-06-30 |
267.55 |
$71.32 |
3.75 |
| 2020-03-31 |
316.38 |
$74.71 |
4.23 |
| 2019-12-31 |
296.73 |
$87.53 |
3.39 |
| 2019-09-30 |
232.82 |
$76.92 |
3.03 |
| 2019-06-30 |
233.87 |
$70.20 |
3.33 |
| 2019-03-31 |
236.38 |
$71.29 |
3.32 |
| 2018-12-31 |
300.92 |
$66.08 |
4.55 |
| 2018-09-30 |
353.31 |
$68.29 |
5.17 |
| 2018-06-30 |
290.24 |
$60.83 |
4.77 |
| 2018-03-31 |
273.82 |
$66.53 |
4.12 |
| 2017-12-31 |
318.57 |
$59.57 |
5.35 |
| 2017-09-30 |
313.12 |
$60.76 |
5.15 |
| 2017-06-30 |
271.36 |
$54.74 |
4.96 |
| 2017-03-31 |
273.42 |
$54.06 |
5.06 |
| 2016-12-31 |
261.39 |
$56.18 |
4.65 |
| 2016-09-30 |
288.53 |
$55.68 |
5.18 |
| 2016-06-30 |
222.89 |
$52.04 |
4.28 |
| 2016-03-31 |
239.95 |
$47.15 |
5.09 |
| 2015-12-31 |
282.37 |
$42.89 |
6.58 |
| 2015-09-30 |
268.35 |
$47.41 |
5.66 |
| 2015-06-30 |
372.33 |
$53.46 |
6.96 |
| 2015-03-31 |
389.19 |
$49.61 |
7.85 |
| 2014-12-31 |
312.88 |
$46.10 |
6.79 |
| 2014-09-30 |
304.92 |
$44.17 |
6.90 |
| 2014-06-30 |
290.63 |
$40.51 |
7.18 |
| 2014-03-31 |
281.93 |
$38.54 |
7.32 |
| 2013-12-31 |
257.69 |
$36.48 |
7.06 |
| 2013-09-30 |
221.92 |
$34.40 |
6.45 |
| 2013-06-30 |
198.36 |
$33.25 |
5.97 |
| 2013-03-31 |
177.54 |
$30.92 |
5.74 |
| 2012-12-31 |
134.91 |
$29.44 |
4.58 |
| 2012-09-30 |
137.53 |
$28.16 |
4.88 |
| 2012-06-30 |
133.08 |
$26.53 |
5.02 |
| 2012-03-31 |
116.14 |
$26.33 |
4.41 |
| 2011-12-31 |
101.44 |
$26.55 |
3.82 |
| 2011-09-30 |
85.86 |
$25.66 |
3.35 |
| 2011-06-30 |
98.55 |
$24.97 |
3.95 |
| 2011-03-31 |
67.72 |
$23.48 |
2.88 |
| 2010-12-31 |
61.80 |
$22.66 |
2.73 |
| 2010-09-30 |
51.73 |
$21.28 |
2.43 |
| 2010-06-30 |
43.74 |
$21.54 |
2.03 |
| 2010-03-31 |
52.90 |
$22.29 |
2.37 |
| 2009-12-31 |
49.31 |
$21.71 |
2.27 |
| 2009-09-30 |
46.57 |
$22.81 |
2.04 |
| 2009-06-30 |
41.62 |
$21.62 |
1.92 |
| 2009-03-31 |
48.32 |
$20.86 |
2.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$30.847B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
